The Secret Surveillance Capitalism That Suffuses Medicare

By MICHAEL MILLENSON

Imagine a government program where private contractors boost their bottom line by secretly mining participants’ personal information, such as credit reports, shopping habits and even website logins.

It’s called Medicare.

This is open enrollment season, when 64 million elderly and disabled Americans choose between traditional fee-for-service Medicare and private Medicare Advantage (MA) health plans. MA membership is soaring; within a few years it’s expected to encompass the majority of beneficiaries. That popularity is due in no small part to the extra benefits plans can provide to promote good health, ranging from gym membership and eyeglasses to meal delivery and transportation assistance.

There is, however, an unspoken price for these enhancements that’s being paid not in dollars but in privacy. To better target outreach, some plans are routinely accessing sophisticated analytics that draw upon what’s euphemistically labeled “consumer data.” One vendor boasts of having up to 5,000 “certified variables for every adult in America,” including “clinical, social, economic, behavioral and environmental data.” 

Yet while companies like Facebook and Google have faced intense scrutiny, health care firms have remained largely under the radar. The ethical issue is obvious. Since none of this sensitive personal information is covered by the privacy and disclosure rules protecting actual medical data, it is being deliberately used without disclosure to, or explicit consent by, consumers. That’s simply wrong.

But a more fundamental concern involves the analyses themselves.

The claims of predictive accuracy have never been subjected to public third-party scrutiny examining possible bias or even basic effectiveness. Since more than half of all Black and Hispanic Medicare beneficiaries already choose MA plans, that’s a flashing warning sign.

The human and financial stakes – the government pays MA plans some $350 billion annually – are high. The failures of transparency urgently need to be addressed. 

A recent Federal Trade Commission (FTC) forum explored what’s been termed “surveillance capitalism.” FTC chair Lina Khan notes that Americans often “have limited insight into what information is being collected about them and how it’s being used, sold or stored.”

That’s particularly true here. Giant data brokers, privately-funded startups and others are using artificial intelligence (AI) techniques to uncover both patient risk factors and the best way to influence behavior.  For instance, an affiliate of billionaire Richard Branson’s Virgin Group said its analytics showed that Philadelphia Eagles fans would be likelier to join a disease management program if they were contacted by text rather than email.

The for-profit mining of consumer data for health purposes is a somewhat paradoxical outgrowth of public health research, which has long stressed the need to address so-called “social determinants of health” (SDOH). SDOH refers to the environment in which people are born, live, learn, work and play. Many health care organizations now use questionnaires to try to discover who has SDOH issues that might make them more vulnerable to later developing expensive medical problems.

But questionnaires are often completed partially, inaccurately or not at all. The data mining mavens believe they’ve found a better and more scalable solution. Because MA plans are paid a flat rate per member, effective SDOH interventions can yield both better health and a healthy return on investment. Moreover, the health systems and physician groups that actually provide care are increasingly signing contracts that incent wellness, both for Medicare patients and others. When you add in the renewed national attention to health equity, the result is an SDOH industry worth $18.5 billion as of July, 2021, according to one estimate.

While it’s difficult to identify which organizations use the data and how, specifics sometimes slip out. 

At a 2019 Department of Health and Human Services seminar, a physician executive at a New York City health system, explained how his group applies AI to information gathered from the electronic health record mixed with commercial data.

“For instance, if people don’t live near a bus stop or subway station and haven’t purchased an oil change or wiper blades, we can reach out to ask questions [about mobility],” said the system’s head of population health. That conversation required discretion, Fields added, since revealing why someone was contacted “would be creepy.” 

A Humana slide from that same seminar showed that its Grandkids-on-Demand program, which provides companionship and assistance to lonely seniors, was in part enabled by “consumer information from an external vendor.”

Meanwhile, United Healthcare’s Optum group has said it uses consumer data to “close gaps in care and reduce medical costs.” Separately, an Optum algorithm was identified in 2018 as being unintentionally biased against Black patients.

Humana and United enroll nearly half of all MA members, and in many U.S. counties control at least three-quarters of MA enrollees, according to the Kaiser Family Foundation

An overwhelming 81 percent of Americans believe they have little or no control over the data companies collect on them, according to a Pew Research Center poll. So what should be done about this secret health care surveillance? 

Government regulators could move to mandate transparency, but there’s a simpler path. United’s market-leading MA share has been powered by its long affiliation with AARP. As a senior advocacy group, AARP should immediately demand that United, and all MA plans, disclose their consumer data use. Perhaps that would prod insurers and providers to treat those in their care as genuine partners, not objects.

The Center for Medicare & Medicaid Services should similarly publicly ask MA plans to disclose. That call for “voluntarism” could be echoed by the members of Congress who introduced bipartisan legislation to strengthen data privacy and security. 

 But beyond disclosure, the government should demand that researchers be allowed to examine the assertion that the data miners are providing predictive accuracy without bias. This is crucial, and it can be done while protecting intellectual property rights. As one researcher put it, “We have to make sure this pays off both for the health care system and the patient.”

That’s exactly the right standard. I believe “big data” could provide a genuine leap forward in finding and helping individuals whose health is at risk. But good intentions are not good enough to protect consumers.  Health care decisions relying upon secret information secretly used is a risk vulnerable Americans should not have to take.

Michael Millenson is a consultant specializing in quality of care, patient empowerment and web-based health. He is President of Health Quality Advisors, and an adjunct associate professor of medicine at Northwestern University’s Feinberg School of Medicine

from The Health Care Blog https://ift.tt/eQLj5qp

Sylvana Sinha, CEO, Praava Health

Sylvana Sinha is CEO of Praava Health, a primary & specialty care network based in Dhaka, Bangladesh. While the average American may only think about Bangladesh when there’s some disaster on the news it’s a country of 165m+ people with a GDP per capita exceeding India’s. It lacks excellent health services for its growing middle class, and that’s the gap Praava Health is filling. I learned a lot about Sylvana, Bangladesh, and Praava in this quick interview —Matthew Holt

from The Health Care Blog https://ift.tt/Zuhaost

Pfizer’s Biotech Strategy: When a “Market Force” Partners with a “Market Mover”

by JESSICA DAMASSA, WTF HEALTH

The synergistic relationship between biotech’s and biopharma’s can dramatically change the way new drugs and vaccines are bought to market – helping advance innovation on BOTH sides in a very mutually beneficial way. I’ve got an inside look at how Pfizer is working with emerging biotech start-ups, thanks to this in-depth chat with Pfizer’s Senior Vice President of Business Innovation, Kathy Fernando.

Kathy is not only responsible for developing relationships with biotech’s on behalf of Pfizer, BUT during the pandemic she led Pfizer’s mRNA scientific strategy, which was integral to its ability to rapidly develop the Covid-19 vaccine. We geek out on the “cool science” that mRNA is – AND the new platforms that biotech’s are bringing to the table – and talk about the impact both are making on the business of Big Pharma, the hot biotech investment space, and, most importantly, patients.

We also get into a bigger conversation about innovation in the Life Sciences industry – with great insights that can be extended to the rest of healthcare quite easily. I ask point blank: Pfizer is a gigantic, global biopharma company…Why wouldn’t it do these types of innovations internally, in-house themselves? Why partner outside?

Kathy explains the magic that is unlocked when a “market force” partners with a “market mover” for the sake of innovation, and the lessons learned are far reaching and applicable no matter where you are in health innovation.

How is Pfizer looking at new models for collaborating with biotech companies? What are the key characteristics of Pfizer’s culture of innovation that have newly emerged or deepened as a result of their work on the Covid vaccine during the pandemic? We dive deep into the biopharma-biotech model and all it brings in terms of new science, breakthrough therapies, and brand-new business opportunities. Watch now!

from The Health Care Blog https://ift.tt/vELacSH

Does Surviving The Plague Mean You Will Eventually Contract An Autoimmune Disease?

BY MIKE MAGEE

This Fall, I am teaching a 4-week course on “How Epidemics Have Shaped Our World” at the President’s College at the University of Hartford. It is, of course a timely topic, but also personally unnerving as we complete a third year under the shadow of Covid-19.

Where does one begin on a topic such as this? Yale historian, Frank M. Snowden, in his book “Epidemics and Society: From the Black Death to the Present”, made his intentions obvious. He would begin with the plaque. Why? His answer, “The word ‘plague’ will always be synonymous with ‘terror’”, and especially references:

Virulence: “It strikes rapidly, causing excruciating and degrading symptoms, and, if untreated, achieves a high case fatality rate (CFR)…of at least 50%.”

Speed: “Its progress through the body was terrifyingly swift. As a rule, the plague killed within days of the onset of symptoms, and sometimes more swiftly.”

Target: “It preferentially targeted men and women in the prime of life (and)…left in its wake vast numbers of orphans, widows and destitute families.”

Reaction: “…communities afflicted with plague responded with mass hysteria, violence, and religious revivals… people sought to assuage an angry god.”

Scapegoating: “Frequently, vigilantes hunted down foreigners and Jews and sought out witches and poisoners.”

One might also argue, as Snowden does, that the plague also launched the field of Public Health which included quarantines, penthouses, masking, and sanitary cordons. But knowledge of causality (Yesinia pests, passed along by common flea from ship rat to humans) and treatment (modern sanitary movement and modern antibiotics) was slow to reveal itself.

But that’s “ancient history.” Not so fast. Last week, Nature published a paper authored by Jennifer Klunk PhD and her associates from McMaster University’s Ancient DNA Centre focused on modern genes that they now believe owe their existence to the Black Plague’s human rampage nine centuries ago.

The Black Death is estimated to have killed 30% to 50% of Europeans between 1347 -1351. But DNA anthropologist, Hendrik Poinar, a colleague of Klunk’s, focused on one nearly forgotten graveyard in London, the East Smithfield graveyard. It was purchased by King Edward III as a plague pit for mass burials, accepting “guests” for a small moment in time between 1348-1349. Later survivors of the plague, who died of other causes, were buried on top of plague victims in 1350 and beyond. The dated samples of DNA included cadavers from before, during, and shortly after the plague event.

The hypothesis: “…this concentrated mass death event could have caused hugely selective pressure on the genetics of the individuals who survived, who would likely have passed down genes that allowed them to survive the plague.”

The findings: 

  1. DNA samples were obtained from 318 cadavers in London and 198 cadavers in a Danish cohort. Burial position allowed investigators to pin time of death relative to the plague event. By comparing pre- and post-plague samples, the investigators were able to isolate 35 genes that were more prevalent in those that survived the plague. Cross-referencing with the Danish sampling, they whittled the list down to 4 genetic targets. 
  2. One of the four variations was associated with the endoplasmic reticulum aminopeptidase 2 (ERAP2) gene which codes a protein whose purpose is to slice and dice invading viral and bacterial proteins, and post or display them on the surface of macrophages. These “warning flags” allow the protective macrophages to identify what invaders next to gobble up and destroy. The presence of the gene appears to have offered a 40% increased chance of surviving the plague.
  3. Modern day humans can have one, two, or no working copies of the ERAP2 gene. Investigators armed with human blood samples from all three varieties then tested them against the Yersinia pests bacteria. As expected, samples with immune cells having two working copies of the ERAP2 gene were most effective in killing Y. pestis.

The hitch:

But possessing this survival gene comes with one important downside. Modern day humans who have the two working copies of ERAP2 are also more likely to inappropriately attack their own living cells. Specifically, rates of Crohn’s Disease, Rheumatoid Arthritis, and Lupus are higher in this cohort than in those without the survival gene variant. The implications are obvious to all, and enough to bring Darwin back from the grave. As University of Arizona population geneticist said, “This is a truly impressive paper. The implications of the potential speed and power of natural selection in immune genes are wild.”

The protective, and potentially autoimmune causing variant, lives on in 45% of modern day Brits. Thus epidemics will continue to shape our world, raising difficult risk/benefit questions along the continuum of infectious disease, immunity, chronic inflammation, and modern day vaccine policy.

_____________________________________________________________________________

Mike Magee MD is a Medical Historian and the author of “CODE BLUE: Inside the Medical Industrial Complex.”

from The Health Care Blog https://ift.tt/hApEuSJ

Future of Big Data in Health? LexisNexis® Risk Solutions Says Next-Gen Tokenization & Health Equity

BY JESSICA DaMASSA, WTF HEALTH

Data-juggernaut LexisNexis® Risk Solutions is making a big data play in healthcare, launching a new capability that allows for unprecedented accuracy in the kind of de-identified data that payers, providers, and pharma are clamoring to use for everything from cutting admin expenses to improving patient outcomes and health equity.

Jeff Diamond, President & General Manager of The Health Care Business of LexisNexis® Risk Solutions and Andrea Green, Director of Healthcare Strategy, SDoH, drop in for a chat about all things VERY big data, including this concept of “next-gen tokenization” which leverages LexisNexis’s massive amount of consumer data as a way to connect data “personas” to create a much more accurate, actionable, and longitudinal view of a patient.

The thing to understand is just how much health data LexisNexis® Risk Solutions is working with and who they are working with it for: 90% of commercial payers in the US; 8 of the Top 10 pharma manufacturers; 10 of the Top 10 retail pharmacies; and hundreds of hospital systems.

So, how is this data “turned” into insightful and actionable information that appeals to this top-tier clientele? Jeff and Andrea walk through use case after use case that demonstrate the ‘business of healthcare’ applications of the LexisNexis data processing platform (think patient safety, risk stratification, claims analytics, provider directory, etc.) with special emphasis on how their new analytics suite, focused on Social Determinants of Health data, is helping with such clinical initiatives as improving diversity in clinical trials and providing predictive insights about patients who might need mental healthcare support. The data comes to life in this one. Watch now!

from The Health Care Blog https://ift.tt/rpH6DXG

Art Is in the Eye of the Computer

BY KIM BELLARD

It turns out that I’ve been writing about Generative AI without even realizing there was something called Generative AI, such as articles about the robot artist Ai-Da, the AI image creator DALL-E, or patent protection for AI inventors.  Generative AI refers to AI that strives not just to process and synthesize data but to actually be creative.  It’s starting to both become more widespread and to attract serious attention from investors.  

James Currier of investment firm NFX sees “Generative Tech” as the next big thing: “If crypto hadn’t happened, we’d probably be calling THIS Web3.”  He distinguishes Generative AI from Generative Tech as: 

Some have called it “Generative AI,” but AI is only half of the equation. AI models are the enabling base layers of the stack. The top layers will be thousands of applications. Generative Tech is about what will actually touch us – what you can do with AI as a partner.

He predicts Generative Tech will generate “trillions of dollars of value.”  I’m hoping that healthcare is paying attention.

—————-

Let’s start with OpenAI and its DALL-E 2.  DALL-E 2 got much attention earlier in the year with its startlingly unique images, and now is more broadly available, with more than 1.5 million users.  The Wall Street Journal calls its images “amazing – and terrifying.”  

OpenAI is overseen by a non-profit company, and its mission is “to ensure that artificial general intelligence benefits all humanity,” presumably meant to draw the distinction from AI developed by for-profit companies (such as DeepMind, which is owned by Alphabet).  Its charter explicitly states that it seeks that AI/AGI “is used for the benefit of all, and to avoid enabling uses of AI or AGI that harm humanity or unduly concentrate power.”  Its “primary fiduciary duty is to humanity.” 

Microsoft invested $1b in 2019 (in return for OpenAI using Azure as its cloud partner and giving Microsoft priority in brining new technologies to market), and The Wall Street Journal now reports that the companies are in “advanced talks” for a new round of funding. OpenAI is valued at nearly $20b.

Then there’s Stability AI, which just announced a $101 million funding round that values the company at $1b. It bills itself as “the world’s first community-driven, open-source artificial intelligence (AI) company,” with a slogan “AI by the people, for the people.”  Emad Mostaque, founder and CEO, states: 

Stability AI puts the power back into the hands of developer communities and opens the door for ground-breaking new applications. An independent entity in this space supporting these communities can create real value and change.

Its competitors to DALL-E are Stable Diffusion, released in August, “a powerful, free and open-source text-to-image generator” that already has been licensed by 200,000 developers, and DreamStudio, its consumer-facing image product that has a million registered users.  

A New York Times article noted that Stable Diffusion has limited safety filters, which has made it popular among artists and has led to some, shall we say, objectionable images.  Mr. Mostaque is undeterred, telling the NYT: “We trust people, and we trust the community, as opposed to having a centralized, unelected entity controlling the most powerful technology in the world.”  

He made a similar point to TechCrunch: “Nobody has any voting rights except our employees — no billionaires, big funds, governments or anyone else with control of the company or the communities we support. We’re completely independent.”  

Still another Generative AI company, Jasper, also scored a funding round last week, with the $125 million round valuing it at $1.5b.  Jasper bills itself as an “AI Content Platform,” including both generating text and text-to-images.  Interestingly, it uses OpenAI’s GPT-3 to power the platform.  

Jasper CEO Dave Rogenmoser says: “Generative AI represents a major breakthrough in creative potential, but it’s still inaccessible and intimidating to many. Jasper is working to bring AI to the masses and teach people how to leverage it responsibly so that businesses and individuals can better convey their ideas.”  

I’d be remiss if I didn’t at least mention Anthropic, which has raised close to $800 million, or MidJourney, which boosts 3 million users taking advantage of image generator on its Discord server.  Anthropic is set up as a public benefit corporation, and is “working to build reliable, interpretable, and steerable AI systems,” while MidJourney describes itself as “a small self-funded team focused on design, human infrastructure, and AI.”  I’m sure there are others.

—————

Joanna Stern, writing in the WSJ, marvels: “The stuff once found in AI research labs is now making it into our homes and offices…For decades, we’ve been hearing AI is going to change how we interact with computers and the world. These tools may be the first time most of us recognize it in action.”

There’s already much concern about the “black box” of AI – we may not know how or why AI comes up with things – and the implicit biases that may be built it (e.g., most healthcare data sets will include the results of the inequities in our current healthcare system).  Stability AI’s Mr. Mostaque told NYT: “Ultimately, transparency, not top-down control, is what will keep generative A.I. from becoming a dangerous force,” and I hope he’s right – but I’m not sure he is.

I love the idea of “democratizing” AI, putting it in our homes and offices.  I like the idea that some of this is happening through non-profits, like OpenAI.  I’m highly intrigued that some of it is open source, like Stability AI.  And I’m wondering what the impetus in healthcare will be to bring it to our care and to our daily lives. 

If Mr. Currier is remotely right that Generative Tech will unleash trillions of dollars in value, healthcare is not going to be untouched.  I’d love to see a collection of our healthcare giants – health systems, health plans, pharma, etc. – pool their data for use by a non-profit focused on AI for healthcare.  I’d like that AI not just be better supportive tools for clinicians, but also to be creative, up to and including “AI physicians,” whatever they may be.  And I think it’d be cool if much of this work could be open source and aimed at the masses.    

Mr. Currier predicts: “In the next 10 years, we will expect software to collaborate with us. It will be the new normal. Steve Jobs said in 1980 that the Apple personal computer was a bicycle for the human mind. You might say that Generative Tech is a rocketship for the human mind.”  

Buckle up: it’s going to be a bumpy ride.  

Kim is a former emarketing exec at a major Blues plan, editor of the late & lamented Tincture.io, and now regular THCB contributor.

from The Health Care Blog https://ift.tt/pcQPzYF

How Is Salesforce a Catalyst for the Consumerization of Healthcare? The Magic Formula is CRM + EMR

By JESSICA DaMASSA, WTF HEALTH

How is Salesforce thinking about the healthcare consumer? I had the chance to ask Salesforce’s SVP & GM of Health & Life Sciences, Amit Khanna, about it from both a product — and a lexicon – standpoint at Dreamforce 2022.

Words matter. So, Salesforce’s use of “customer” when talking about our usual “patients” or “health plan members” or “clinical trial participants” is a bit jarring at first, in the sense that it forces the issue of “patient centricity” to the extreme… to a “customer is always right” place, at least for me. I ask Amit about that terminology, its intentionality, and how he thinks his clients across the healthcare ecosystem are doing when it comes to embracing this new term and the new way of thinking it requires in order to truly activate it.

On the product side, we dive into Salesforce’s BIG launch this year: Salesforce Genie. This is cool in the Health & Life Sciences biz for a number of reasons, mostly because it is the manifestation of that consumerization idea. Real time data, a holistic “customer profile” (aka longitudinal patient record) – these are the things that consumers are used to across industries, says Amit, and the new product release focuses on integrating these for payers, providers, med tech companies, pharma and more. How could these features drive change in the healthcare ecosystem? Amit gives a glimpse of what Salesforce thinks is the ‘big win,’ specifically when it comes to that “wholistic customer profile” and the idea that an EMR and CRM can co-exist to serve different purposes in healthcare.

from The Health Care Blog https://ift.tt/Z1OGsDl

Sticks and Stones…

BY KIM BELLARD

According to the old saying, sticks and stones may break your bones, but names can never hurt you.  I’m not sure that still applies in a social media environment that can have real impacts on mental health of both teenagers and adults, but I have to note that healthcare seems to be pretty sensitive about who calls whom what.  

I’ll start with a new study from The Mayo Clinic about whether patients addressed their physicians by their first name.  It’s a tricky thing to get a gauge on; one could do surveys of both populations, or implant observers in exam rooms, but these researchers had the clever idea of examining how patients addressed their physician when using portal messaging.  They looked at over 90,000 messages from nearly 15,000 patients, with about 30,000 messages from 15,000 patients including a physician’s name (first or last).

The researchers don’t seem to have provided an overall percent of patients using the doctors’ first name, but they did report:

  • Female doctors were twice as likely as male doctors to be called by their first name;
  • DOs were similarly almost twice as likely as MDs to have their first name used;
  • Primary care doctors were 50% more likely than specialists;
  • Female patients were 40% less likely to use first names when addressing their physician.

The authors noted that they don’t know if physicians had expressed preferences about how they should be addressed, but warned: 

The pattern of addressing physicians with different titles based on gender, degree, and specialty may be forms of bias…Whether being informally addressed by other medical professionals or patients, untitling (not using a person’s proper title) may have a negative impact on physicians, demonstrate lack of respect, and can lead to reduction in formality of the physician-patient relationship or workplace.

In a New York Times article about the study, Debra Roter, an emeritus professor of health, behavior and society at Johns Hopkins’ Bloomberg School of Public Health, said: “Doctors might find it [patients using first names] is undermining their authority.  There’s a familiarity that first names gives people.”  However, doctors calling patients by their first name also carries risks, she acknowledged: “It could infantilize the patient or establish the paternalism of the doctor.”

Similarly, in an accompanying commentary, two female physicians (who were not involved in the research) state: “Use of formal titles in medicine and many other professions is a linguistic signal of respect and professionalism,” although they also add: “Such respect in professional communication should be bidirectional, as medical students learn early in training to ask patients how they prefer to be called during medical encounters.”

Most of my physicians must have missed those classes.  

I’ll note that pharmacists these days have PharmD’s, and physical therapists have DPTs, but few of us have qualms about addressing them by their first name.  Lawyers have a JD, but don’t usually insist on being addressed by the title.  University professors and judges are the only two other professions I can think of with expectations about being called by their title instead of their name.  Make of that what you will.  

I don’t know what most physicians prefer to be called, but I know what they hate to be called: providers. I don’t know how many op-ed pieces, tweets, LinkedIn posts, etc. I’ve seen over the years in which physicians complain about the practice.  It’s been associated with how the Nazis minimalized Jewish physicians in 1930’s Germany, called “a powerful tool to confuse and dehumanize a physician,” and led to warnings that “the adaptation of this terminology led to medicine being thought of only as a business, a commoditization of care.”  

Using “provider” to describe physicians, physicians say, disrespects them, understates their years of training, confuses patients, causes “moral injury” to physicians, and may lead, or at least contribute to, physician burnout.  A rose by any other name might still smell as sweet, but a doctor by that term is, apparently, catastrophic.   

I have a pretty good guess as to how physicians who object to being referred to as a provider probably feel about being called by their first name.

While we’re being sensitive, some of us have an issue with being referred to as a patient.  I’ve written before that use of the term is a design problem.  It’s an implicit expectation that we should literally be patient (think of all that time we are expected to just wait), and trust in the greater expertise of physicians; as Dr. Roter noted, it infantilizes the patient and perpetuates the paternalism in the physician/patient relationship.  Moreover, it ignores our existence outside the healthcare system, failing to acknowledge that we have lives outside of it and how those lives impact our health.

As Matthew Zachery recently wrote about the practice, “We are no longer people.”  He goes on to elaborate:

We are products on a shelf, numbers on a page, ink stains on a fax transmission, and zeroes and ones existing only in data centers polluting the earth with their carbon footprints. Patients today are loss-leading, actuary-derived, health-economic meat on a stick.

And to think that some physicians believe that it is using “provider” which led to the commercialization of health care.

Mr. Zachery prefers the term “consumer,” as does my friend Jane Sarasohn-Kahn, but I have to admit that I don’t like that term much better.  We don’t do much intelligent shopping in health care: we don’t really have the right tools, not much in the system is oriented towards encouraging us to try, and there are too many health episodes when we have neither the time nor inclination to consume wisely.  

The bigger problem, as I’ve also written about before, is that, forget healthcare: we’re not really very good consumers of anything.  The concept of a “rational consumer” is a “myth,” says psychologist Peter Noel Murray.  We’re swayed by too many superficial factors that often bear little relevance to quality or value, whether that is healthcare, mobile phones, or automobiles.    

So here’s where I come down: to all the people working in healthcare, or those using healthcare services, who have issues with what they are called: get over it. If that’s the problem in healthcare you are focused on, you are focusing on the wrong problem.  Healthcare has much bigger problems, that need more immediate solutions, and I hate that anyone is spending any extra time or emotional energy on this particular issue.

Treat people with respect; treat them as individuals, whether they are doctors, people receiving services, the person cleaning up, or anyone else.

Kim is a former emarketing exec at a major Blues plan, editor of the late & lamented Tincture.io, and now regular THCB contributor.

from The Health Care Blog https://ift.tt/cI9lbMs

NEW Today! Health System Patient Comms Startup Well Health Becomes Artera

BY JESSICA DaMASSA

Gotta love a new name! Well Health, arguably one of the best-funded digital front door and patient communications startups you’ve never heard of (they’ve raised just under $100 million with little to no fanfare) is today announcing their new moniker, Artera.

Founder & CEO Guillaume de Zwirek breaks the news with us and talks about the strategy behind the name change from both a brand and a business standpoint. Artera is in the (still) hot health tech infrastructure space, selling a platform that health systems can easily integrate into their EMR systems, patient portals or other practice management software to easily send text messages, emails, or other communications to patients.

We get into the details about Artera’s business model, 500+ provider org client base (and what Gui is hearing about their current business challenges) and find our way into a big discussion about digital health funding, that whole bubble thing, health tech startup layoffs, and where Gui thinks the market is headed next. Bottom line: Some interesting comments here (starting around 18.30 mark) about how this might actually help healthcare in the long run.

from The Health Care Blog https://ift.tt/sljGT64

A Country Doctor Reads: What if Burnout Is Less About Work and More About Isolation? (NYT)

BY HANS DUVEFELT

This weekend I read a piece in The New York Times that put a slightly different slant on what burnout, in the case of physician burnout, is or is caused by. We have heard theories from being asked to do the wrong thing, like data entry, to “moral injury” to my favorite, “burnout skills“, when you keep trying to do the impossible because people praise you when you pull it off.

Tish Harrison Warren’s piece is a dialog between her and psychiatrist/author Curt Thompson. He focuses on isolation as a driver of burnout:

Assume that if you’re burned out, your brain needs the help of another brain. Your brain is not going to be OK until or unless you have the experience and opportunity of being in the presence of someone else who can begin to ask you the kind of questions that will allow you to name the things that you’re experiencing.

The moment that you start to tell your story vulnerably to someone else, and that person meets you with empathy — without trying to fix your loneliness, without trying to fix your shame — your entire body will begin to change. Not all at once. But you feel distinctly different.

I’m not as lonely in that moment because you are with me. And I sense you sensing me. That’s a neural reality.

I have written about burnout many times. The NYT article made me remember that I once also wrote about missing the doctors lounge and how I once tried to start a slack group among my colleagues. It never really took off but I think the point about isolation feeding burnout is very valid. Back when there were doctors lounges, we would talk with colleagues. Even in the office when I started out we scribbled our chart notes very quickly and then we would have time and space to discuss our cases or other things with our colleagues. Now we are tied to the computers, feeding the big machine that controls each of our lives.

As often before, my thoughts go to a James Taylor song, one about working in isolation to feed a big machine – Millworker:

Then it’s me and my machine

For the rest of the morning

For the rest of the afternoon

And the rest of my life

And, later:

And I have been the fool

To let this manufacturer

Use my body for a tool

But, when all is said and done, I am not burned out, as I say in one of my videos. I work at looking beyond my obstacles and I focus on my patient encounters and my curiosity.’

But I wish I wasn’t as isolated as I am, in part simply due to the pandemic. I mean, even medical staff meetings are virtual these days. Like Hollywood Squares…

from The Health Care Blog https://ift.tt/tROKXYf